新生兒假死の治療殊に天然ビタカンファー(Allo-p-oxocamphor)と合成ビタカンファー(Trans-π-oxocamphor)との比較に就て

概要

論文の詳細を見る
1) Prior to the employment of Vitacampher the first srade of asphyxia yielded a mortality rate of 3 per cent. After it came into general use no case of death has been reported in the first grade of asphyxia. The mortality or asphyxia neonatorum of the second grade, which was as high as 55.9 per cent before Vitacampher was discovered, has been reduced to 16 per cent with allo-p-oxocamphor, and to 25 per cent with trans-π-oxocamphor. The difference between the percentages of the latter two could not be ascribed to the difference between the effects of the chemicals used, for this difference may be influenced not only by the causes of asphyxia but also by the number of cases reported. At any rate, it is clear that the mortality has definitely been reduced by the use of Vitacampher. 2) The effective dose of Vitacampher was relatively small, varying from the minimum of 0.5 cc to the maximum of 3.0 cc during the early days of its use. Since then it has been used in increasing doses, and in our second report published in 1935 relatively large doses have been used. Vitacampher today is commonly used in large doses inasmuch as the drug is known to have little toxic or cumulative effect. The chemicals were used in relatively small doses at first because it was necessary to determine the proper dose and to observe their pharmacological actions, as reported in the earlier papers. 3) The time from delivery of the baby to its first crying took about eight minutes with either allo-p-oxocamphor or trans-π-oxocamphor. No difference was observed between them. 4) The average amount of trams-π-oxocamphor used was 3.4 cc exceeding that of allo-p-oxocamphor which was used in the first report. No harmful secondary reaction has been observed. 5) Experimental Cases. Recently trans-π-oxocamphor was used in treating some infants with asphyxia neonatorum of the second grade. The results obtained are as follows: In 2 cases out of 13 the fetal heart tone was audible before delivery, but it was quite impossible to hear it immediately after birth so that these were considered as cases of still-birth. In another case one could hear the heart tone after birth, which improved for a time after the injection of Vitacampher, although the drug could not prevent the aggravation of general condition and the ultimate death of the child. This was presumably the result of some injurious effects produced by the application of forceps. It is impossible to determine the cause of death because the case was not brought to autopsy.
社団法人日本産科婦人科学会の論文
1951-11-01

著者

安井修平
東京逓信病院

新生兒假死の治療殊に天然ビタカンファー(Allo-p-oxocamphor)と合成ビタカンファー(Trans-π-oxocamphor)との比較に就て

スポンサーリンク

概要

著者

関連論文

スポンサーリンク